Stocklytics Platform
Asset logo for symbol RNLX
Renalytix AI plc
RNLX49
$0.35arrow_drop_up15.24%$0.04
Penny Stock
Asset logo for symbol RNLX
RNLX49

$0.35

arrow_drop_up15.24%

Performance History

Chart placeholder
Key Stats
Open$0.30
Prev. Close$0.30
EPS-0.76
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$27.89M
PE Ratio-
LOWHIGH
Day Range0.29
0.30
52 Week Range0.22
3.62
Ratios
EPS-0.76

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$738.87B
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$382.01B
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About Renalytix AI plc (RNLX)

Renalytix AI plc (RNLX) is a company that specializes in artificial intelligence solutions for the prediction and management of kidney disease. With a strong focus on innovation and technology, Renalytix AI is at the forefront of using advanced analytics and machine learning algorithms to unlock the potential of big data in the field of nephrology. By utilizing its proprietary KidneyIntelX platform, Renalytix AI aims to improve the early detection and treatment of kidney disease, ultimately leading to better patient outcomes and reduced healthcare costs.
One of the key advantages of Renalytix AI's technology is its ability to analyze and interpret complex molecular patterns in urine and blood samples. By integrating multiple data sources, including electronic medical records and genetic profiles, the KidneyIntelX platform can provide a comprehensive assessment of an individual's risk for kidney disease progression. This personalized approach enables healthcare providers to tailor treatment plans and interventions based on each patient's unique needs, resulting in more effective and targeted care.
Sector
Healthcare
Industry
Health Information Services
CEO
Mr. James R. McCullough M.B.A.
Headquarters
New York
Employees
102
Exchange
NASDAQ
add Renalytix AI plc to watchlist

Keep an eye on Renalytix AI plc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for Renalytix AI plc (RNLX)?
For Renalytix AI plc (RNLX), the 52-week high is $3.3, which is 838.83% from the current price. The 52-week low is $0.22, the current price is 59.77% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Renalytix AI plc (RNLX) a growth stock?
Renalytix AI plc (RNLX) has shown an average price growth of 0.41% over the past three years. It has received a score of -2 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Renalytix AI plc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Renalytix AI plc's (RNLX) price per share?
The current price per share for Renalytix AI plc (RNLX) is $0.35. The stock has seen a price change of $0.05 recently, indicating a 15.25% change. This reflects the stock's recent market performance and investor sentiment.
help
What is Renalytix AI plc (RNLX) stock price performance year to date (YTD)?
As of the latest data, Renalytix AI plc (RNLX) has a year-to-date price change of -17.29%. Over the past month, the stock has experienced a price change of -0.26%. Over the last three months, the change has been -43.69%. Over the past six months, the figure is 13.02%.
help
Is Renalytix AI plc (RNLX) a profitable company?
Renalytix AI plc (RNLX) has a net income of -$46.22M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 20.6% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.15K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.4M, with a revenue growth rate of 14.58%, providing insight into the company's sales performance and growth. The gross profit is $701K. Operating income is noted at -$42.36M. Furthermore, the EBITDA is -$33.07M.
help
What is the market capitalization of Renalytix AI plc (RNLX)?
Renalytix AI plc (RNLX) has a market capitalization of $28.85M. The average daily trading volume is 752.95K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level